DNA DAMAGE RESPONSE INHIBITION
TARGETING CANCER BY INHIBITING DNA DAMAGE RESPONSE
A novel therapeutic strategy exploiting cancer's Achilles heel: inability to survive without active DNA repair mechanisms.
Learn More About Our ApproachAbout Moltech Innovations
Our Vision
At Moltech Innovations, our vision is to be a global leader in biotechnology, developing solutions that have a positive impact on human health and the environment.
Our Innovation
We are committed to innovation and constantly pushing the boundaries of what is possible in biotechnology, developing new and groundbreaking solutions that address some of the world's most pressing health challenges.
Our Expertise
With decades of combined experience in biotechnology, our team has the expertise and knowledge to develop solutions that are effective, safe, and sustainable.
AI-DEVELOPED NOVEL THERAPEUTICS
Targeting Cancer · Preventing Repair of DNA Lesions in Cancers
Moltech Innovations is dedicated to revolutionizing oncology drug discovery. By leveraging advanced AI, we aim to drastically reduce development timelines and costs, bringing life-saving medicines to market that could replace traditional chemotherapy.
Preventing Repair of DNA Lesions in Cancers
The Challenge: Collateral Damage From Current Cancer Therapies
Current cancer therapies indiscriminately damage DNA, affecting both healthy and cancerous cells. Tumours adapt by up-regulating DNA repair pathways, leading to resistance. Combination therapy that we are developing blocks cancer cells' DNA repair ability, preventing the survival of cancer cells.
A Paradigm Shift: Selective Killing Through DNA Repair Inhibition
Cancer cells have high levels of spontaneous DNA damage due to rapid proliferation and genomic instability. Normal cells have low DNA damage because they divide infrequently and maintain genomic stability. Rather than adding more DNA damage, we target the cancer cells' DNA repair pathways.
Wider Therapeutic Window
Our innovative strategy creates a therapeutic window where cancer cells are selectively killed, while healthy tissues are spared, offering a more precise and less damaging treatment alternative.
Our Investors Help us Improve and Modernise Drug Discovery
